Shares of BeiGene, a biopharmaceutical company, experienced a pre-market soar of 5.62% on October 4th, 2024. This upward movement in the stock price can be attributed to the company's announcement of granting share options and restricted share units (RSUs) to its employees and directors.
According to filings with the Hong Kong stock exchange, BeiGene granted 22,713 American depositary shares (ADSs), equivalent to 295,269 underlying shares, as share options to 12 employees. These options will vest over a period of 10 years. Additionally, the company granted 90,542 restricted share units in ADSs, equivalent to 1,177,046 underlying shares, to 223 recipients.
The granting of share options and RSUs is a common practice for companies to incentivize and retain their employees and directors. This announcement from BeiGene is seen as a positive signal by investors, reflecting the company's efforts to motivate its workforce and align their interests with those of the shareholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.